R01C:Preservation and Growth of Human Follicles (4 of 10)
R01C:人类卵泡的保存和生长(10 中的 4)
基本信息
- 批准号:7649510
- 负责人:
- 金额:$ 42.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-30 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgeAlgorithmsBiocompatible MaterialsBiological PreservationCancer PatientCancer SurvivorClinicalCommunicationCounselingCryopreservationDataDecision MakingDevelopmentDisciplineEconomicsEmergency SituationEthicsFailureFamilyFemaleFertilityFertilization in VitroGoalsGrowthHumanIn VitroLifeMalignant NeoplasmsMethodsMusOncologistOocytesOvarianOvarian FollicleOvarian TissuePatient RecruitmentsPatientsPharmaceutical PreparationsPhysiciansPremature Ovarian FailureProductionProviderRecruitment ActivityRelative (related person)Reproductive BiologyResearch ProposalsRiskRisk AssessmentRoleScienceSpecialistStagingSteroidsSystemSystemic TherapyTechnologyTestingTimeToxic effectTranslatingTreatment ProtocolsTreatment outcomeWomanWorkanalytical methodcancer therapychemotherapeutic agentchemotherapychildhood cancer survivorcombinatorialimprovednonhuman primateoocyte maturationphrasesreproductivereproductive axisresponse
项目摘要
Ten years ago, the phrase 'families after cancer1 for most women would have been an oxymoron if
contemplated at all. Today, due to the impressive rise in young female cancer survivors, this is not only a
well-used phrase, but also an issue that women increasingly want addressed. As the lexicon is being
established, the boundaries are expanding to encompass the fertility needs of childhood cancer survivors for
whom fertility-conserving options are limited. The role of the emerging oncofertility specialist is to navigate
through the available options and provide individualized counseling to patients. To provide this kind of
authoritative information to women in different age brackets, with different treatment regimens, it is
necessary to evaluate the reproductive axis and its response to cancer treatment in a rigorous manner. The
ability to recruit patients through the large National Physicians Cooperative (P30B) will provide sufficient
power to correlate treatment and outcome data in a comprehensive and thorough manner. In Specific Aim 1,
we will develop combinatorial analytical methods and a predictive algorithm to assess the Risk of Impending
Premature Ovarian Failure (RIPOF, pronounced rip off) in young women treated with chemotherapeutics for
their cancers. These data will improve information exchange between the provider and the patient about the
risk and timeframe of impending premature ovarian failure. We will also use the established murine ovarian
culture system to test a broad panel of chemotherapeutics and establish endpoints that can be used to
rapidly assess the likely fertility impact of any new or existing drugs that are introduced into the oncologists'
arsenal (Specific Aim 2). Therefore, the relative toxicity of new chemotherapeutic agents on in vitro follicle
survival and maturation (in vitro risk, IVR) will be investigated. Finally, the major goal of the project is to
develop methods to grow immature human ovarian follicles into the mature, fertilizable stage (Specific Aim
3). We will translate recent breakthroughs at the interface of material science and reproductive biology into
clinically-proven technology that can provide additional fertility options to those who may lose fertility due to
cancer treatment.
十年前,如果大多数女性的癌症之后的一句话的家庭将是矛盾的话,如果
根本考虑过。今天,由于年轻女性癌症幸存者的令人印象深刻的增长,这不仅是
使用良好的短语,但也是女性越来越想解决的问题。词典正在
建立的边界正在扩展,以涵盖儿童期癌症幸存者的生育需求
持有生育能力的选择有限。新兴的Oncofertility专家的作用是导航
通过可用的选择,并为患者提供个性化的咨询。提供这种
给不同年龄段的妇女的权威信息,具有不同的治疗方案,这是
以严格的方式评估生殖轴及其对癌症治疗的反应所必需的。这
通过大型国家医生合作(P30B)招募患者的能力将提供足够的
以全面而彻底的方式将治疗和结果数据相关联。在特定的目标1中,
我们将开发组合分析方法和预测算法,以评估即将来临的风险
在接受化学治疗药物治疗的年轻妇女中
他们的癌症。这些数据将改善提供者和患者之间有关的信息交换
即将发生早产卵巢衰竭的风险和时间表。我们还将使用已建立的鼠卵巢
培养系统测试一系列化学治疗剂并建立可用于用于的终点
迅速评估引入肿瘤学家的任何新药物或现有药物的可能产生影响
阿森纳(特定目标2)。因此,新化学治疗剂对体外卵泡的相对毒性
将研究生存和成熟(体外风险,IVR)。最后,该项目的主要目标是
开发方法将未成熟的人类卵巢卵泡发展成成熟的,可肥的阶段(特定目的
3)。我们将在材料科学界面和生殖生物学界面的最新突破中转化为
临床经验丰富的技术,可以为可能因由于
癌症治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Teresa K Woodruff其他文献
MALE RESULTS OF THE SPARE STUDY: SURVEY FOR PRESERVATION OF ADOLESCENT REPRODUCTION
- DOI:
10.1016/s0022-5347(08)61917-5 - 发表时间:
2008-04-01 - 期刊:
- 影响因子:
- 作者:
Tobias S Kohler;Sarah Chan;Amul M Shah;Laxmi A Kondapalli;Marybeth Gerrity;Teresa K Woodruff;Robert Brannigan - 通讯作者:
Robert Brannigan
Teresa K Woodruff的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Teresa K Woodruff', 18)}}的其他基金
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
- 批准号:
8415387 - 财政年份:2012
- 资助金额:
$ 42.61万 - 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
- 批准号:
8768923 - 财政年份:2012
- 资助金额:
$ 42.61万 - 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
- 批准号:
8730764 - 财政年份:2012
- 资助金额:
$ 42.61万 - 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
- 批准号:
8929340 - 财政年份:2012
- 资助金额:
$ 42.61万 - 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
- 批准号:
9013074 - 财政年份:2012
- 资助金额:
$ 42.61万 - 项目类别:
Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System
3D 微生理系统中的离体女性生殖道整合
- 批准号:
9105454 - 财政年份:2012
- 资助金额:
$ 42.61万 - 项目类别:
相似国自然基金
无线供能边缘网络中基于信息年龄的能量与数据协同调度算法研究
- 批准号:62372118
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
面向年龄相关性黄斑变性诊断的迁移学习算法研究
- 批准号:62371328
- 批准年份:2023
- 资助金额:53 万元
- 项目类别:面上项目
基于信息年龄的自组网分布式及时信息调度算法研究
- 批准号:62102232
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
异质动态网络上年龄结构传染病模型及算法研究
- 批准号:11701348
- 批准年份:2017
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
视网膜年龄相关性黄斑病变OCT图像的三维分割算法研究
- 批准号:61401294
- 批准年份:2014
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
- 批准号:
10462257 - 财政年份:2023
- 资助金额:
$ 42.61万 - 项目类别:
Sleep and Cardiometabolic Subgroup Discovery and Risk Prediction in United States Adolescents and Young Adults: A Multi-Study Multi-Domain Analysis of NHANES and NSRR
美国青少年和年轻人的睡眠和心脏代谢亚组发现和风险预测:NHANES 和 NSRR 的多研究多领域分析
- 批准号:
10639360 - 财政年份:2023
- 资助金额:
$ 42.61万 - 项目类别:
Sharp Neonatal Research Institute Clinical Center (Sharp NRI-CC)
夏普新生儿研究所临床中心 (Sharp NRI-CC)
- 批准号:
10683030 - 财政年份:2023
- 资助金额:
$ 42.61万 - 项目类别:
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
一种用于治疗 B 系急性淋巴细胞白血病/淋巴瘤的新型 VpreB1 抗体药物偶联物
- 批准号:
10651082 - 财政年份:2023
- 资助金额:
$ 42.61万 - 项目类别:
Move and Snooze: Adding insomnia treatment to an exercise program to improve pain outcomes in older adults with knee osteoarthritis
活动和小睡:在锻炼计划中添加失眠治疗,以改善患有膝骨关节炎的老年人的疼痛结果
- 批准号:
10797056 - 财政年份:2023
- 资助金额:
$ 42.61万 - 项目类别: